

# An evaluation of Motivational (MI) plus Cognitive Therapy (CBT) for Schizophrenia and Substance Misuse

<b>Submission date</b> 29/08/2003	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
<b>Registration date</b> 01/09/2003	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 03/08/2009	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Christine Barrowclough

**Contact details**  
Academic Division of Clinical Psychology  
University of Manchester  
School of Psychiatry and Behavioural Sciences  
Education and Research Centre  
Wythenshawe Hospital  
Wythenshawe  
Manchester  
United Kingdom  
M23 9LT  
+44 (0)161 291 5881  
[christine.barrowclough@man.ac.uk](mailto:christine.barrowclough@man.ac.uk)

## Additional identifiers

**Protocol serial number**  
G0200471

# Study information

## Scientific Title

## Acronym

Motivational Interventions for Drug and Alcohol Use in Schizophrenia (MIDAS)

## Study objectives

The aim of the study is to evaluate the benefits of the adjunct of a psychological treatment over standard available care for patients with schizophrenia and a co-morbid drug or alcohol problem.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Not provided at time of registration

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Mental and behavioural disorder

## Interventions

The experimental treatment (MI plus CBT) will consist of motivational interviewing to increase motivation to reduce substance use; CBT for help with both substance use reduction and symptom management; and relapse prevention strategies. Patients randomised to receive MI plus CBT will be offered up to 26 sessions over 12 months with treatment being located at home or clinic according to the patient's choice. The MI plus CBT treatment will be in addition to standard psychiatric care. The control group will receive standard psychiatric care alone.

## Intervention Type

Other

## Phase

Not Specified

## Primary outcome(s)

Either readmission to hospital for reason related to psychosis or death from any cause/not admitted to hospital in the 12 month post-treatment period.

## Key secondary outcome(s)

Added as of 6 February 2007: Measures of symptomatology, relapses, substance misuse and health economic analyses.

**Completion date**

02/05/2009

## Eligibility

**Key inclusion criteria**

1. Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM IV) diagnostic criteria for schizophrenia, schizophreniform or schizoaffective disorder
2. Recorded contact and treatment from mental health services at the point of recruitment
3. Prescribed anti-psychotic medication
4. Alcohol use exceeding 28 units for males, 21 units for females on at least half the weeks in the previous 3 months
5. DSM IV diagnosis of drug and/or alcohol dependence or abuse
6. No significant history of organic factors implicated in the aetiology of psychotic symptoms
7. English speaking
8. Informed patient consent
9. Having a fixed abode

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

See inclusion criteria

**Date of first enrolment**

03/10/2004

**Date of final enrolment**

02/05/2009

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**  
**Academic Division of Clinical Psychology**  
Manchester  
United Kingdom  
M23 9LT

## **Sponsor information**

### **Organisation**

University of Manchester (UK)

### **ROR**

<https://ror.org/027m9bs27>

## **Funder(s)**

### **Funder type**

Research council

### **Funder Name**

Medical Research Council (MRC) (UK)

### **Alternative Name(s)**

Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

### **Funding Body Type**

Government organisation

### **Funding Body Subtype**

National government

### **Location**

United Kingdom

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2009		Yes	No